This research service considers the biologics market in Brazil. It covers the market’s move toward greater regulation and outlines the impact of specific patent expirations. An analysis of monoclonal antibodies, blood factors, insulin, filgrastim, interferon, growth hormones, and erythropoietin is provided. This service also highlights key market drivers and restraints in addition to breaking down the current and forecasted competitive scenario. The base year of the study is 2010, and the forecast period is 2011 to 2017.